Home › Compare › KIERF vs ABBV
KIERF yields 3.45% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, KIERF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KIERF + ABBV for your $10,000?
Kier Group plc primarily engages in the construction business in the United Kingdom and internationally. The company operates through three segments: Construction, Infrastructure Services, and Property. It constructs power stations, roads, bridges, railways, tunnels, and buildings for public and private sectors including schools, hospitals and prisons; and provides maintenance services for the UK road, rail, and utilities infrastructure, as well as reactive repairs. The company also offers maintenance and compliance services; housing maintenance; and facilities management services, such as cleaning, grounds maintenance, security, and pest control, as well as environmental services; and invests in and develops property schemes and sites. In addition, it provides design and business services, including project and programme management, architecture and landscape design, civil and structural engineering, building services engineering, building information modelling, cost management, strategic estates advice, building and condition surveys, ICT design and installation, business case development and feasibility, and advisory services. Kier Group plc was incorporated in 1992 and is based in Salford, the United Kingdom.
Full KIERF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.